Navigation Links
FDA Approves 'Plan B' Pill for 17-Year-Olds
Date:4/22/2009

Decision is latest involving controversial birth-control drug

WEDNESDAY, April 22 (HealthDay News) -- Responding to a federal judge's directive, the U.S. Food and Drug Administration said Wednesday that it will now allow 17-year-olds to get the controversial "morning-after" birth control pill without a doctor's prescription.

In 2006, the FDA said it would limit over-the-counter access to the pill, also known as Plan B, to women 18 and older. But U.S. District Judge Edward R. Korman ruled last month in a New York lawsuit that the FDA had to reconsider whether to make the drug available to all women, regardless of age, without a prescription. He ordered the agency to let 17-year-olds get the drug, and separately to evaluate whether all age restrictions should be lifted.

"On March 23, 2009, a federal court issued an order directing the FDA, within 30 days, to permit the Plan B drug sponsor to make Plan B available to women 17 and older without a prescription," the agency said in a statement issued Wednesday afternoon on its Web site. "The government will not appeal this decision. In accordance with the court's order, and consistent with the scientific findings since 2005 by the Center for Drug Evaluation and Research, FDA sent a letter to the manufacturer of Plan B that the company may, upon submission and approval of an appropriate application, market Plan B without a prescription to women 17 years of age and older."

Plan B is an extra high dose of regular birth control that needs to be taken within 72 hours of unprotected intercourse to be effective. Essentially, the drug prevents pregnancy by delaying ovulation. It does not interrupt an already implanted pregnancy.

Religious conservatives object to Plan B, saying it is the equivalent of an abortion pill because it can prevent a fertilized egg from attaching to the uterus, and could also encourage premarital sex.

Supporters of broader access to Plan B argue that it is safe and effective in preventing unwanted pregnancy, and could also help reduce the number of abortions. They also contend that the FDA's decision to limit access to the drug to women 18 and older was a concession to the conservative views of then-President George W. Bush and his administration.

When the FDA announced its approval of over-the-counter sale of the Plan B pill in August 2006, after three years of delay, the decision came with stiff restrictions: Women under the age of 18 could not purchase the pills without a doctor's prescription.

"Our assessment is that this younger age group would strongly benefit from consultation with a health-care provider before using the product," Dr. Steven Galson, director of the FDA's Center for Drug Evaluation and Research, said during a 2006 news conference. "The application did not contain enough information about this age group to make us comfortable to do the switch fully for those younger people."

The age restriction was also meant to ease concerns for pharmacists, Galson said. "We have all kinds of restrictions that click in at 18," he said. "We thought for this program to practically work, the age 18 made sense."

The FDA originally approved Plan B as a prescription drug in 1999. It is manufactured by Duramed Research Inc. of Bala Cynwyd, Pa.

More information

For more on Plan B, visit the FDA.



SOURCES: April 22, 2009, news release, U.S. Food and Drug Administration; Aug. 24, 2006, news conference with Steven Galson, M.D., director, U.S. Food and Drug Administration Center for Drug Evaluation and Research


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
2. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
3. FDA Approves New Indication for Wyeths TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
4. U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
5. FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
6. FDA Approves Two Hologic HPV Tests
7. U.S. Food and Drug Administration Approves New Female Condom
8. Congress Approves FY2009 Omnibus Appropriations Bill with $900 Million for The Global Fund
9. FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout
10. State Health Department Approves Closure Plan for Brownsville Tri-County Hospital
11. NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves 'Plan B' Pill for 17-Year-Olds
(Date:2/28/2017)... ... 2017 , ... Science-based sleep company Level Sleep ... HCI students, faculty, and alumni can acquire Level Sleep’s unique sleep system in ... community to receive educational content on sleep and proper biomechanics that will empower ...
(Date:2/28/2017)... ... ... BrightStar Care Marietta announced that it has received the 2017 Best of Home ... only to top-ranking home care providers, based on client satisfaction scores gathered by Home ... from across the country who have proven their ability to provide the highest quality ...
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze Health & Wellness Center ... as its New Guest Director. , Brandl is a dynamic and influential ... He began his professional career at Omnium Worldwide, now known as West Corporation, ...
(Date:2/27/2017)... ... 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working as ... Now, she writes about God, when she isn’t swimming as a performing mermaid. , Her ... BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, before ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... 2014. The company had 800 customers and 2,250 RCEs at the time of ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... Inc. (Nasdaq: IONS ) today reported that ... pro forma operating income of $25.8 million and $665.2 ... Company also reported a GAAP loss from operations of ... significant accomplishments for Ionis, culminating in the U.S. approval ... broad label. The approval of SPINRAZA is a testament ...
(Date:2/28/2017)... ... Research and Markets has announced the addition of ... report to their offering. The global active pharmaceutical ... 239.8 billion by 2025. The rising prevalence of lifestyle-induced & age-related ... forecast period. Advancements in recombinant molecular technologies and high capitalization for ...
(Date:2/28/2017)... SAN FRANCISCO, Calif. , Feb. 28, 2017 ... today announced that it will report its fourth ... close on Tuesday, March 7, 2017.  Rigel senior ... conference call and webcast at 5:00pm Eastern Time ... Participants can access the live conference ...
Breaking Medicine Technology: